This page shows the latest Amryt news and features for those working in and with pharma, biotech and healthcare.
Amryt Pharma’s Lojuxta (lomitapide) for homozygous familial hypercholesterolaemia (HoFH) was ranked as a Level 3.
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Dr Joe Wiley, chief executive officer of Amryt, said: “I am pleased to welcome Jordi to our senior management team as the company’s head of Europe. ... His significant commercial experience of European markets will help us to drive and further
Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin. ... Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...